Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
Urology Product Preview: Testosterone agent meets efficacy endpoint in phase III studies
August 11th 2014Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
Best of AUA 2014: Female Urology/Incontinence/ Urodynamics
July 10th 2014Adonis K. Hijaz, MD, presents the take home messages on female urology/incontinence/urodynamics from the AUA annual meeting in Orlando, FL, including studies on mesh outcomes and the overactive bladder treatment mirabegron (Myrbetriq).
Clinicians say active surveillance is effective but rarely recommend it
June 30th 2014The majority of urologists and radiation oncologists feel active surveillance is an effective and underused modality for managing low-risk prostate cancer; however, few of these specialists would recommend this strategy to patients, according to recent survey results.
FDA proposes reclassification of transvaginal mesh
May 5th 2014The FDA recently issued two proposed orders that, if finalized, would reclassify surgical mesh for transvaginal pelvic organ prolapse from a moderate-risk device (class II) to a high-risk device (class III) and require manufacturers to submit a premarket approval application for the agency to evaluate safety and effectiveness.